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Abstract
Introduction: Chronic kidney disease (CKD) in children, despite the progress in science and
technology,  is  still  a  serious  challenge.  Early  CKD  detection  gives  a  chance  of  early
therapeutic intervention and lowering the progression of the disease. According to several
publications indicating the possible use of alfa-Klotho (αKL) and tumour necrosis factor alfa
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(TNFα) for the early detection of the disease in adults, an attempt was made to evaluate their
usefulness in the paediatric population.
Material and methods: The study group consisted of 42 patients with CKD with a mean age
of 10.7 years (18 girls and 24 boys). The control group involved 21 healthy children with a
mean age of 8.4 years (11 girls and 10 boys). Anthropometrical parameters and blood pressure
were  taken  and  routine  biochemical  tests  were  performed  in  the  whole  group.  The
concentrations  of  TNFα  and  αKL  in  serum  and  urine  were  determined  by  enzyme
immunoassay.
Results: Children from the CKD group showed a statistically significant difference in serum
TNFα and αKL in comparison to the control group. There was no significant relationship
between  the  evaluated  markers  and  sex,  presence  of  hypertension,  or  proteinuria  in  the
children. The mean αKL serum concentration was higher in patients on dialysis compared to
the group of conservatively treated children, whereas the values of TNFα in serum and urine,
as well as the αKL in urine, did not differ significantly in these groups. A significant positive
correlation was found between serum αKL concentration and serum creatinine, but there was
no other correlation between serum αKL or TNFα concentration and any of the measured
anthropometric and laboratory parameters.
Conclusions: Serum TNFα and αKL levels in children with chronic kidney disease, although
being statistically different compared to the group of healthy children, except for the correla-
tion of serum αKL and creatinine, showed no other correlations to the most parameters used
for chronic kidney disease evaluation including, eGFR. Their usefulness in the early detection
of kidney dysfunction in children was not proven.
Key words:  children; chronic kidney disease; TNF alpha; alpha Klotho; renal replacement
therapy
Introduction 
Chronic kidney disease (CKD) is a serious health problem worldwide, with increasing in-
cidence and prevalence. Progressive kidney damage with a subsequent loss of glomerular fil-
tration function ultimately results in the initiation of renal replacement therapy (RRT) [1]. The
epidemiology of CKD in children originates mostly from the data available of stage 5 CKD
patients on renal replacement therapy (RRT), which causes data on the scale of the problem in
the paediatric population to be underestimated. In the global perspective, the prevalence of
chronic kidney disease stage 2 or lower is reported to be approximately 55–60 per 1 million of
age-related population, with an approximate mean incidence of 11–12 cases per year per mil-
lion, according to European researchers [2, 3]. The dominant causes in children are congenital
kidney and urinary tract defects (CAKUT) and glomerulonephritis.  Reports draw attention
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also to the growing problem of obesity and diabetes in the paediatric population, predicting an
increase in the prevalence of CKD [4]. This problem also concerns children born prematurely
or born with low body weight [5].
Symptomatology of  CKD differs  depending on the stage  of  the disease.  In  the initial
stages the phenomenon of glomerular hyperfiltration occurs, and the treatment consists of
pharmacological nephroprotection, regulation of acid-base and water-electrolyte balance dis-
orders, the use of a diet with reduced protein intake, and an adequate fluid balance. The ure-
mic state develops, in which toxic metabolism products accumulate in the blood, resulting in a
life-threatening biochemical  and immunological  dysregulation  requiring  renal  replacement
therapy [6, 7].
αKL is  a  single-pass  transmembrane  protein  expressed  mostly  in  the  kidney,  choroid
plexus, and parathyroid gland. It occurs in two forms: transmembrane and soluble. Membrane
αKL acts as co-receptor for fibroblast  growth factor-23 (FGF23), enabling merging to the
FGF receptor (FGFR) [8]. This FGF23-αKlotho-FGFR complex activates mechanisms crucial
for maintaining mineral homeostasis and hormone regulations (PTH, FGF23, and 1,25-(OH)2
vitamin D3) in kidney, bone, intestine, and parathyroid gland, but also shows antiaging proper-
ties and downregulates insulin growth factor (IGF). The extracellular domain of αKL sepa-
rated from the cell surface functions as an endocrine substance and is found in blood, urine,
and cerebrospinal  fluid.  Its  multiple renal and extra-renal functions such as antioxidation,
modulation of renal ion channels, inhibition of apoptosis, anti-senescence, and suppression of
Wnt-signalling and the renin-angiotensin-aldosterone system (RAA) have been studied by re-
searchers in recent years [8–11]. Serum Klotho deficiency is found in both acute and chronic
kidney injury [9, 12, 13], and it seems that the reduction of the αKL level might be related di-
rectly to the reduction in the number of functioning nephrons, which potentially qualifies αKL
to the group of early markers of CKD progression. In view of the numerous data on Klotho’s
renoprotective effect, as well as those suggesting that the loss of this function may be among
the causes involved in the development of renal disease [12, 14], learning the exact mecha-
nisms of action within the kidneys requires careful analysis.
TNFα is a cytokine produced mainly by macrophages, but also many other cells of the
monocytic lineage. There are two forms of TNFα: membrane-bound and soluble form, which
is formed from the membrane form by the TNFα converting enzyme. TNFα acts through
transmembrane receptor TNFR1, which is expressed in most mammalian tissues, and TNFR2
– highly regulated and expressed mostly in immune system cells [15, 16]. It induces several
biological  effects,  such  as  apoptosis,  cytotoxicity  to  neoplastic  cell  lines,  stimulation  of
phagocytosis, induction of acute phase protein production in the liver, stimulation of the for-
mation of fibroblasts and osteoclasts, increased body temperature, and others. The key role of
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this cytokine in the immunomodulation processes is also emphasized, which is the basis for
maintaining the body's immune homeostasis [15–17]. Many studies have shown the involve-
ment of TNFα in the pathogenesis of both acute and chronic kidney disease [18–20]. How-
ever, taking into account the function in both inflammatory and immunoregulatory processes,
it can be hypothesised that this cytokine is responsible not only for the pro-inflammatory ef-
fect, but also for the immunosuppressive effect in CKD. In adult studies, TNFα receptor levels
are higher in the presence of impaired renal function, and they correlate with an increase in
creatinine, and a decrease in eGFR and albuminuria [21–22]. It is believed that albuminuria it-
self may increase TNFα levels, but this issue has not been thoroughly investigated in children.
Most of the studies concerning αKL and TNFα were carried out in adults. Both of these
proteins, due to the numerous functions that bind them to chronic kidney disease progression
in adults, require separate analysis in the paediatric population. 
The aim of our study was to evaluate the usefulness of TNFα and αKL measurements in
serum and urine as biomarkers of early renal function decline in children diagnosed with
CKD.
Material and methods
The study group (CKD) consisted of 42 patients aged 2 to 18 years with CKD (18 girls
and 24 boys). The causes of CKD were CAKUT (45.2%), polycystic kidney disease (19%),
tubulointerstitial  nephritis  (14.2%),  glomerulonephritis  (11.9%),  nephronophthisis  (4.7%),
renal toxicity (2.5%), and tubulopathy (2.5%). The mean CKD duration was 5.9±4.5 years.
Twenty-six children (62%) were diagnosed with hypertension. The children from the study
group were treated pharmacologically with antihypertensive agents, iron formulas, vitamin D,
calcium carbonate,  and  sodium bicarbonate.  Ten  children  (23%)  were  treated  with  renal
replacement  therapy  (RRT)  using  peritoneal  dialysis  (7  patients)  or  maintenance
haemodialysis (3 patients). On admission, weight, height, and blood pressure were taken and
routine biochemical tests were performed. Body mass index (BMI) was calculated using the
formula [BMI = body weight (kg)/height (m)2]. Estimated glomerular filtration rate (eGFR)
was  calculated  according  to  the  Schwartz  formula  (mL/min/1.73  m2)  [23].  Additionally,
albuminuria (mg/day) using 24 h urine collection was evaluated.
The  control  group  consisted  of  21  healthy  children  aged  1  to  18  years  admitted  for
procedures of one-day surgery or patients with monosymptomatic nocturnal enuresis (11 girls
and 10 boys). All children presented no signs of kidney disease, had no symptoms of acute
infection, and were in good clinical condition. Anthropometric measurements and the age of
the study subjects and controls are presented in Table 1. The average age, weight, height, and
BMI in the study group and the control group did not differ significantly.
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Both groups of patients were also examined for the assessment of FGF21 concentration in
urine and blood serum. It was described in a separate paper [24], which is part of one research
project.
The study was approved by the Bioethics Committee of the Medical University of Silesia
in Katowice (resolution No. KNW/0022/KB1/110/I/12 of 03.12.2013), and written consent
from parents or legal guardians, and/or the patients (above 13 years of age) was obtained.
Blood samples (3–5 mL) for laboratory tests were taken in Eppendorf tubes during an
examination related to periodic control in the outpatient clinic in the morning (8:00–9:00).
After  centrifugation  1000 for  15  minutes  at  4°C,  the  serum was  stored  at  –20°C until
assayed. Urine samples (50–100 mL) were collected at the same time as the blood samples,
and also kept at –20°C until evaluation (CKD group only). Concentration of albumin in 24-
hour urine collection, as well as albumin and creatinine concentration in urine samples, was
performed. 
Determination of TNFα and αKL levels
Determination of serum and urine concentrations of TNFα and αKL was performed in the
Chair and Department of Medical and Molecular Biology, Faculty of Medical Sciences in
Zabrze, SUM in Katowice.
The concentration of the soluble αKL form was determined by ELISA (enzyme-linked
immunosorbent assay) using commercially available kits from IBL International (Hamburg,
Germany) according to the methods provided by the manufacturers by measuring extinction
in a Quant Universal Microplate Spectrophotometer (Biotek Instruments Inc., Vinooski, VT,
USA). The sensitivity of the kit was 6.15 pg/mL, with 3.5% in-series error and 11.1% out-of-
series error.
TNF-α concentration in blood serum and urine samples was determined by the enzyme
immunoassay method from the TNF-α determination ELISA kit,  Diaclone (Diaclone SAS,
France), cat. No. 950.090.096, according to the manufacturer's instructions. Immunocomplex
detection was based on the reaction with a recombinant anti-TNF-α molecule conjugated to
horseradish  peroxidase  and  TMB solutions  as  a  substrate  (TMB Substrate,  slow  kinetic,
Sigma,  USA).  Absorbance  readings  were  carried  out  using  a  Universal  Microplate
Spectrophotometer — µQUANT from BIO-TEK INC (head office of Bio-Tek, California,
USA), at a wavelength of 450 nm, and processing of results - using the KCJunior computer
program (Bio-Tek, USA).  The sensitivity of the set covered by 0.8 pg/mL,   in-series error
5.43%, and out-of-series error 7.37%.
Statistical analysis
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A database was prepared in a Microsoft  Excel  spreadsheet.  For statistical  calculations
STATISTICA software licensed v. 10.0 was used (StatSoft Inc., Tulsa, USA). The level of
statistical significance was assumed at p < 0.05. The arithmetic mean, median, minimum and
maximum value, lower and upper quartile, and standard deviation were calculated. For all
parameters, the compatibility of their distributions with a normal distribution was checked
with Shapiro-Wilk test. For variables with normal distribution, the parametric test was used (t-
test  for  independent  variables  in  comparative  analyses  and Pearson’s  test  for  analyses  of
correlation). For other variables, nonparametric tests were applied (Mann-Whitney U-test for
comparisons and Spearman’s rank correlation test for analyses of correlation).
Results
The results of routine laboratory tests are presented in Table 2. Children with CKD had
elevated  mean  daily  urinary  albumin  excretion  and  albumin/creatinine  ratio.  Total  serum
protein and albumin levels remained within the normal range. Patients with proteinuria were
significantly older (13.6 vs. 9.6 years/p < 0.05). Mean eGFR in CKD group (with an average
of 47.87 ± 20 mL/min/1.73 m2) and standardized levels of creatinine clearance were lowered
showing no sex differences.  Analysing the lipid profile,  although the CKD group of girls
presented increased mean total cholesterol, the average level of total cholesterol, HDL, and
LDL cholesterol fractions were within the normal range and the triglyceride concentration
was elevated in the whole CKD group. Among the CKD group, only two patients presented
with obesity (BMI > 95 pc) and nine with increased values of systolic blood pressure (SBP >
97 pc). The mean MAP value was 79.1±10.0 mmHg.
In children with CKD, both analysed parameters (TNFα and αKL) in serum showed a
statistically  significant  difference  in  comparison  with  the  control  group  (Fig.  1).  Further
analyses among patients from the CKD group showed no differences in the values of serum or
urine αKL and TNFα levels in relation to sex and the presence of proteinuria in children.
There was a difference for the mean αKL serum concentration, which was higher in patients
on dialysis compared to the group of conservatively treated children, whereas the values of
TNFα in serum and urine as well as the αKlotho in urine did not differ significantly in these
groups (Fig. 2A–C).
A  statistically  significant  positive  correlation  was  found  between  serum  αKL
concentration and serum creatinine (r = 0.4437; p = 0.01) and urine αKL (r = 0.5866; p =
0.01). A negative correlation was found between serum TNFα and white blood cell count (r =
–0.5202; p = 0.000) and a positive correlation was found with urine TNFα (r = 0.4753; p =
0.046). There was no other correlation between serum αKL or TNFα concentration and any of
the measured anthropometric and laboratory parameters. eGFR correlated negatively with the
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albumin/creatinine ratio (r = –0.4603; p = 0.01),  but no correlation with albuminuria was
found. After adjusting to body mass index (BMI) and body surface area (BSA), we found
positive correlations between αKL/BSA and triglycerides (r = 0.32; p = 0.043) and a negative
correlation between αKL/BMI and serum TNFα (r = –0.5769; p = 0.012).
Urine αKL concentration correlated positively with serum inorganic phosphate (r = 0.399;
p < 0.05) and serum αKL. Urine TNFα correlated positively with total protein concentration (r
= 0.3687; p < 0.05) and serum TNFα. No other statistically significant correlations for urine
αKL or TNFα concentration were found (Tab. 3).
Discussion
The current study documents that inflammatory biomarker TNF-α is significantly ele-
vated in patients with CKD compared to controls without CKD, and anti-ageing factor αKL
significantly decreased, even in the paediatric population.
The manuscript of Hu et al. [9] explains the complicated mechanisms of KL renal and
extra-renal actions. KL deficiency makes the kidney more susceptible to acute insults, delays
kidney regeneration, and promotes renal fibrosis. The phenotypes of KL deficiency and CKD
are very similar regarding gross phenotypes (body weight, growth retardation, life span, fertil-
ity), cardiovascular complications, or bone disease problems. There are some differences in
blood biochemistry regarding mineral metabolism, including PTH (normal or low vs. ele-
vated), vitamin D (elevated vs. decreased), and calcium level (slightly elevated vs. normal or
low), but both states show elevated phosphate levels. We did not observe serious deviations in
the parameters of calcium-phosphate metabolism in the studied patients; however, the entire
group of patients had elevated PTH levels. Urinary KL and serum phosphate correlated posi-
tively, but no other correlation was found.
So far, it has been shown that many cell types have a very low baseline appearance of
Klotho mRNA, but few of them express detectable amounts of Klotho protein. So, the effects
caused by it are predominantly dependent on the soluble Klotho concentration [25]. Data from
the literature show that in in vitro experiments soluble Klotho inhibited TNFα-induced ex-
pression of adhesion molecules ICAM-1, VCAM-1, and NF-κB activation in human umbilical
vascular endothelial cells (HUVECs). In that manner, the integrity of endothelium could be
preserved and endothelial dysfunction could be prevented [26]. A study by He et al. further in-
dicated that Klotho could significantly inhibit induced NF-κB activation and the production of
TNFα in monocytes [27]. In our study, although we confirmed low serum levels of KL and
high levels of TNF, suggesting the lack of  KL inhibition, no correlation was found be-
tween the serum concentration of these compounds. Additionally, TNFα negatively correlated
with the total white cell count.
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Low levels of αKL protein were related to adverse cardiovascular outcomes, as exam-
ined by Sági et al. in adult patients with CKD on haemodialysis, including 24% of patients di-
alyzed due to diabetic nephropathy. Depressed soluble Klotho levels were shown in those pa-
tients, but the authors failed to detect their association with vascular calcifications or confirm
their relationship with inflammatory indices [28]. We also did not confirm the relationship of
Klotho concentration with variables describing blood pressure (SBP, DBP, MAP).
Inflammation and oxidative stress accelerate the decline of kidney function [29-32].
TNF is involved in both of these processes, being not only their promoter but also a factor that
further aggravates these disorders as a result of the CKD progression. Odima et al. investi-
gated  paediatric  patients  on  regular  haemodialysis,  confirming  elevated  oxidative  stress
biomarkers within this group, including TNFα, and their decrease after regular therapy by an-
tioxidant medications for three months. The group of examined children presented a number
of deviations in the biochemical parameters associated with the progression of CKD, includ-
ing elevated PTH levels [33]. Among our studied patients we did not observe a significant in-
crease in TNFα levels in end-stage renal disease, but the levels of calcium, inorganic phos-
phate, and PTH within this group were significantly higher than in the other stages of CKD.
A case–control study among 201 adult CKD patients, performed by Lee et al., sug-
gested that TNFα was associated with the prevalence and severity of CKD. This phenomenon
was independent of conventional CKD risk factors, the presence of cardiovascular disease,
and used medications, including antihypertensive therapy. Additionally, they proposed that al-
buminuria  could  selectively  elevate  TNFα and/or  this  cytokine  concentration  may be  in-
creased as a result of decreased clearance of TNFα in patients with CKD [22]. Our observa-
tions, despite the presence of elevated levels of TNFα in the CKD group, showed no signifi-
cance in the correlation of TNFα, both in urine and serum, to albuminuria, with a simultane-
ous positive correlation between serum TNFα and urinary TNFα, which seems to contradict
the theory of impaired elimination. 
Socha-Banasiak et al., in their study on children and adolescents with obesity, docu-
mented that Klotho levels were associated with body weight. Children with kidney diseases
were excluded from that examination [34]. Our data showed no relationship of  KL levels
with BMI, suggesting that in children with CKD the influence of kidney disease has a greater
impact on Klotho levels than the presence of obesity. Due to TNFα participation in the devel-
opment of obesity and its complications, this problem in the paediatric population was investi-
gated by Goral et al. [35], who found that the group of obese patients did not differ in terms of
results of TNFα levels from the control group. The authors were able to establish only a sig-
nificant positive correlation between TNFα and TG. In the publication of Azevedo et al. [31]
an increased daily TNFα secretion was noted in malnourished children, with an additional
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clear surge of TNFα after contact with LPS, although decreased levels of TNFα in this group
of children were also suggested by other authors. Body composition disorders or malnutrition
are problems that often accompany patients with CKD. In our observations, all the parameters
of lipid metabolism or total  protein levels,  as well  as anthropometric  parameters (weight,
height, BMI), remained without a significant relationship with the TNFα levels, although the
average values of cholesterol fractions fluctuated within high norms, and TG levels were in-
creased in the whole study group.
Urine αKL and TNFα measurements did not show a significant correlation with pro-
teinuria or the diagnosis of arterial hypertension. The same analysis carried out in terms of the
need for dialysis or conservative treatment showed no differences in the levels of urine αKL
and TNFα. These parameters did not correlate additionally with eGFR, creatinine, or the albu-
min/creatinine ratio. A positive correlation was noted between urinary and serum TNFα, uri-
nary and serum αKL, urinary TNFα and serum total  protein levels,  and urinary αKL and
serum inorganic phosphate levels. These observations are inconsistent. While the increase in
phosphate levels may indicate a deterioration in nephron filtration, which may be reflected in
excessive "loss" of αKL by the glomeruli, a similar mechanism is not applicable to TNFα loss.
Jacobson et al. investigated the excretion of urinary oxidative stress biomarkers in children
with CKD during several months of specialist observation [36]. The markers they studied, es-
pecially the baseline parameters, were associated with higher eGFR, lower proteinuria, and
lower risk of renal replacement therapy. The authors noted that despite numerous reports on
the role of oxidative stress in the development of CKD, their determination in urine may re-
flect the current kidney function rather than predict disease progression.
When analysing the activity of TNFα, attention is drawn to the key role of TNFα
receptors TNFR1 and TNFR2, not only as key mediators of TNFα but also as elements of an
independent  pathway  of  renal  injury  and  renal  function  decline  [20].  It  seems  that  the
assessment of TNFR in children with chronic kidney disease may be a more accurate method
of assessing the processes occurring in the course of chronic kidney disease than the analysis
of the TNFα level itself, which certainly requires further studies in the paediatric population
[37, 38].
A major limitation of the study is the small number of examined children with CKD,
which  is  the  effect  of  epidemiological  conditions  and  could  be  solved  by  longer  data
collection or the organization of a multicentre study. Other limitation is the lack of evaluation
of urine TNFα and αKL in healthy patients. Nevertheless, despite the difficulties in observing
the paediatric population, each analysis seems to be an important voice in the discussion on
better understanding of CKD as well as improving patient treatment.
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Conclusions
Serum TNFα and αKL levels in children with chronic kidney disease, although being
statistically different compared to the group of healthy children, except for the correlation of
serum αKL and creatinine, showed no other correlations to most of the parameters used for
chronic kidney disease evaluation, including eGFR. Their usefulness in the early detection of
kidney dysfunction in children was not proven.
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Figure 1. Mean serum αKlotho and tumour necrosis factor alpha (TNFα) concentration in
chronic kidney disease (CKD) and in the control group
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Figure 2A. αKlotho and tumour necrosis factor alpha (TNFα) levels in children with chronic
kidney disease (CKD) depending on sex
Figure 2A. αKlotho and tumour necrosis  factor  alpha (TNFα) levels  in children on renal
replacement therapy (RRT) and conservative treatment (pre-RRT)
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Figure 2C. αKlotho and tumour necrosis factor alpha (TNFα) levels in children with chronic
kidney disease (CKD) depending on proteinuria
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Table 1. Clinical characteristics of evaluated children — children with chronic kidney disease





















































































































Data are presented as mean ± standard deviation; BMI — body mass index; SDS — standard deviation
score; NS — non-significant










Serum albumin [g/L] 44.02 ± 6.25 42.8 ± 7.9 44.8 ± 4.7 NS
Total proteins [g/L] 69.3 ± 7.58 68.23 ± 8.7 70.1 ± 6.7 NS
15
Parathyroid hormone [pg/mL] 184.3 ± 278 296.9 ± 400 104.5 ± 83.2 p < 0.05
Total cholesterol [mmol/L] 4.8 ± 2.2 5.49 ± 3.18 4.29 ± 0.72 NS
HDL-cholesterol [mmol/L] 1.3 ± 0.39 1.165  ±
0.38
1.40 ± 0.38 NS
LDL-cholesterol [mmol/L] 2.74 ± 1.98 3.43 ± 3.02 2.31 ± 0.69 NS
Triglycerides [mmol/L] 1.59 ± 1.02 1.91 ± 1.35 1.36 ± 0.64 NS





Urea [mmol/L] 12.35 ± 8.3 12.67  ±
10.5
12.1 ± 6.5 NS
HCO3 [mmol/L] 21.9 ± 2.3 22.7 ± 2.05 21.3 ± 2.32 p < 0.05
Inorganic  phosphate
[mmol/L]
1.64 ± 0.6 1.68 ± 0.64 1.6 ± 0.58 NS
Total calcium [mmol/L] 2.427 ± 0.23 2.41 ± 0.3 2.44 ± 0.17 NS
White blood cells [G/L] 6.62 ± 2.2 6.34 ± 2.15 6.83 ± 2.26 NS
Haemoglobin [g/dL] 12.17 ± 2.35 11.93  ±
2.85
12.4 ± 1.94 NS
Daily urine albumin excretion
[mg/24 h]





Albuminuria [mg/L] 59 ± 50 30.92  ±
48.3
76.5 ± 43.8 p < 0.01
Albumin/creatinine  ratio
[mg/g creatinine]
423.2 ± 905 328.25  ±
983
484.8 ± 872 NS
Standardized  creatinine
clearance [mL/min/1.73 m2]
49.33 ± 24.15 48.75  ±
25.4
49.8 ± 24.0 NS






Data are presented as mean ± standard deviation;  HDL — high-density lipoprotein; LDL — low-
density lipoprotein; HCO3 — hydrogen carbonate; eGFR — estimated glomerular filtration rate. NS
— non-significant. Significant boys vs. girls p < 0.05
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Table  3. Correlation between αKlotho and tumour necrosis  factor  alpha  (TNFα) concentration  and the results  of  chosen anthropometrical
measurements and biochemical parameters among the group with chronic kidney disease (CKD)
Parameter Serum αKlotho Urine αKlotho Serum TNF Urine TNF
Body weight r  = p = .908 r  = p = .415 r  = p = .088 r  = p = .566
Height r  =  – p = .953 r  = p = .590 r  = p = .082 r  = p = .857
BMI r  = p = .590 r  = p = .237 r  = p = .209 r  = p = .355
Age r  =  – p = .971 r  = p = .705 r  = p = .058 r  = p = .831
SBP r  =  – p = .773 r  = p = .692 r  = p = .643 r  =  – p = .671
DBP r  =  – p = .817 r = 0.1124 p = .527 r  =  – p = .796 r  =  – p = .226
MAP r  =  – p = .852 r  = p = .578 r  = p = .973 r  =  – p = .341
Serum albumin r  =  – p = .948 r  =  – p = .773 r  =  – p = .784 r  =  – p = .531
Total proteins r  =  – p = .626 r  = p = .725 r  = p = .504 r  = p = .032
Parathyroid hormone r  = p = .130 r  =  – p = .787 r  =  – p = .416 r  =  – p = .792
Triglycerides r  = p = .226 r  = p = .086 r  =  – p = .573 r  = p = .389
Serum creatinine r  = p = .003 r  = p = .197 r  =  – p = .956 r  =  – p = .489
Urea r  = p = .683 r  = p = .662 r  = p = .145 r  = p = .881
HCO3 r  =  – p = .898 r  =  – p = .483 r  = p = .298 r  = p = .445
Inorganic phosphate r  = p = .175 r = 0.399 p = .019 r  =  – p = .156 r  =  – p = .390
Total Calcium r  =  – p = .258 r  =  – p = .666 r  =  – p = .758 r  = p = .480
Haemoglobin r  =  – p = .330 r  =  – p = .219 r  = p = .256 r  = p = .745
White blood cell count r  =  – p = .540 r  =  – p = .533 r  =  – p = .000 r  =  – p = .119
Daily urine albumin excretion r  = p = .877 r  = p = .247 r  =  – p = .551 r  =  – p = .570
Albuminuria r  =  – p = .109 r  =  – p = .634 r  =  – p = .183 r  =  – p = .068
Albumin/creatinine ratio r  = p = .637 r  = p = .122 r  =  – p = .820 r  =  – p = .738
Standardized  creatinine  clear- r = 0.064 p = .746 r  =  – p = .999 r  = p = .585 r  = p = .708
EGFR r  =  – p = .301 r  =  – p = .545 r = 0.05 p = .786 r  =  – p = .519
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BMI — body mass index; SBP — systolic blood pressure; DBP — diastolic blood pressure; MAP — mean arterial pressure;  HCO3 — hydrogen
carbonate; eGFR — estimated glomerular filtration rate. Significant correlation coefficients p < 0.
19
